



Final Appraisal Recommendation

Advice No: 2717 – December 2017

Adalimumab (Humira®) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial)

Limited submission by AbbVie Ltd

Recommendation of AWMSG

Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of paediatric chronic non-infectious anterior uveitis in patients from two years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- The Summary of Product Characteristics recommends that paediatric uveitis patients are treated with adalimumab in combination with methotrexate.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3035), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	AbbVie Ltd
Date of first issue	December 2017
Last reviewed	December 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2717:
Adalimumab (Humira®) 40 mg solution for injection (pre-filled pen, pre-filled syringe and vial)
December 2017